Cited 18 times in
Elbasvir/Grazoprevir in Asia-Pacific/Russian Participants With Chronic Hepatitis C Virus Genotype 1 ,4 ,or 6 Infection
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.date.accessioned | 2022-08-16T01:31:44Z | - |
dc.date.available | 2022-08-16T01:31:44Z | - |
dc.date.issued | 2018-04 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/188918 | - |
dc.description.abstract | The prevalence of hepatitis C virus (HCV) infection in Asian countries is high. This study assessed the efficacy and safety of elbasvir/grazoprevir (EBR/GZR) in participants with HCV infection from Asia-Pacific countries and Russia. In this phase 3, randomized, placebo-controlled, double-blind study, treatment-naive participants with HCV genotype (GT) 1, 4, or 6 infection were randomized to EBR 50 mg/GZR 100 mg (immediate-treatment group [ITG]) or placebo (deferred-treatment group [DTG]) once daily for 12 weeks (Protocol PN-5172-067, NCT02251990). The primary efficacy variable was a nonrandomized comparison of sustained virologic response at 12 weeks after the end of therapy (SVR12) for the ITG with a historical control. The primary safety outcome was a randomized comparison between the ITG and DTG. Three hundred thirty-seven participants were randomized to the ITG (n = 251) or DTG (n = 86); 199 (59.2%) participants were Asian, and 250 (74.4%) had HCV GT1b infection. Overall, 232/250 (92.8%) participants in the ITG achieved SVR12 (97.5% confidence interval, 89.1, 96.5). Of the 18 participants who failed to attain SVR12, 1 was lost to follow-up and 17 had virologic failure, 13 of whom had HCV GT6 infection. The incidence of adverse events was similar between participants receiving EBR/GZR and placebo (50.8% versus 51.2%; difference, -0.3%; 95% confidence interval, -12.3, 11.9). Conclusion: EBR/GZR for 12 weeks provides an effective and well-tolerated regimen for chronic HCV GT1 infection in treatment-naive people from Asia-Pacific countries and Russia, particularly for the large population with GT1b infection. EBR/GZR is not recommended for the treatment of individuals with HCV GT6 infection. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Wiley Periodicals | - |
dc.relation.isPartOf | HEPATOLOGY COMMUNICATIONS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Elbasvir/Grazoprevir in Asia-Pacific/Russian Participants With Chronic Hepatitis C Virus Genotype 1 ,4 ,or 6 Infection | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Jacob George | - |
dc.contributor.googleauthor | Eduard Burnevich | - |
dc.contributor.googleauthor | I-Shyan Sheen | - |
dc.contributor.googleauthor | Jeong Heo | - |
dc.contributor.googleauthor | Nguyen Van Kinh | - |
dc.contributor.googleauthor | Tawesak Tanwandee | - |
dc.contributor.googleauthor | Pin-Nan Cheng | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Won Young Tak | - |
dc.contributor.googleauthor | Svetlana Kizhlo | - |
dc.contributor.googleauthor | Konstantin Zhdanov | - |
dc.contributor.googleauthor | Vasily Isakov | - |
dc.contributor.googleauthor | Liwen Liang | - |
dc.contributor.googleauthor | Pauline Lindore | - |
dc.contributor.googleauthor | Joy Ginanni | - |
dc.contributor.googleauthor | Bach-Yen Nguyen | - |
dc.contributor.googleauthor | Janice Wahl | - |
dc.contributor.googleauthor | Eliav Barr | - |
dc.contributor.googleauthor | Michael Robertson | - |
dc.contributor.googleauthor | Paul Ingravallo | - |
dc.contributor.googleauthor | Rohit Talwani | - |
dc.contributor.googleauthor | C‐CORAL Study Investigators | - |
dc.identifier.doi | 10.1002/hep4.1177 | - |
dc.contributor.localId | A00385 | - |
dc.relation.journalcode | J04159 | - |
dc.identifier.eissn | 2471-254X | - |
dc.identifier.pmid | 29761174 | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.affiliatedAuthor | 김도영 | - |
dc.citation.volume | 2 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 595 | - |
dc.citation.endPage | 606 | - |
dc.identifier.bibliographicCitation | HEPATOLOGY COMMUNICATIONS, Vol.2(5) : 595-606, 2018-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.